Gilead Sciences (NASDAQ:GILD) Price Target Raised to $160.00

Gilead Sciences (NASDAQ:GILD) had its price target upped by research analysts at JPMorgan Chase & Co. from $150.00 to $160.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 4.21% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. TD Cowen upped their target price on Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. BMO Capital Markets upped their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Finally, Morgan Stanley increased their target price on Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday. Twenty-five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $141.85.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $153.54 on Wednesday. The firm has a market capitalization of $190.49 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 0.80 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The business has a 50 day simple moving average of $128.39 and a 200-day simple moving average of $121.53. Gilead Sciences has a 1 year low of $93.37 and a 1 year high of $153.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the previous year, the firm earned $1.90 earnings per share. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Geode Capital Management LLC raised its holdings in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after acquiring an additional 727,515 shares during the last quarter. Norges Bank purchased a new position in Gilead Sciences in the 4th quarter valued at $2,617,152,000. Invesco Ltd. grew its stake in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after acquiring an additional 1,618,453 shares in the last quarter. Finally, Amundi increased its holdings in shares of Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after purchasing an additional 1,614,355 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Needham reiterated a Buy and raised its price target to $170, reflecting confidence in HIV momentum and margin expansion. Analyst Note
• Positive Sentiment: Scotiabank raised its price target from $140 to $177 and kept a “sector outperform” stance — a sizable upside vs. the current price that supports further upside expectations. Benzinga
• Positive Sentiment: Cantor Fitzgerald bumped its target to $155 and moved to Overweight, adding institutional buying interest. Benzinga
• Positive Sentiment: Gilead beat Q4 estimates — $1.86 EPS vs. $1.83 consensus and revenue roughly $7.9B — signaling continued strength in its core HIV and liver-disease franchises. Reuters
• Positive Sentiment: Board approved a 3.8% quarterly dividend increase to $0.82 per share (payable March 30), supporting income investors and the yield profile. Business Wire
• Neutral Sentiment: Q4 earnings materials and the conference call transcript provide detail on product trends (Yeztugo launch, HIV portfolio). Useful for modeling revenue cadence but not immediate market-moving by itself. Yahoo Finance
• Negative Sentiment: Gilead’s FY‑2026 guidance came in light: EPS guidance $8.45–$8.85 (consensus ~$8.69) and revenue guidance $29.6–$30.0B vs. ~$30.1B consensus — investors focused on the downside of the outlook. Benzinga
• Negative Sentiment: Because guidance missed some street expectations, shares dipped in after‑hours/extended trading — the immediate market reaction is driven more by forward guidance than yesterday’s beat. MSN

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.